Indaco Venture Partners

IAMA Therapeutics is a biotechnology company focused on advancing neuroscience drug discovery to develop innovative treatments for children with brain disorders. The company aims to address neurological conditions, offering therapeutic solutions that target learning and memory difficulties associated with Down syndrome and the behavioral challenges linked to autism spectrum disorders. By prioritizing the needs of affected children and their families, IAMA Therapeutics strives to create impactful medicines that improve the quality of life for patients while providing essential support to their families.

CamGraPhIC is an integrated photonics platform that focuses on addressing the growing demand for data traffic through its advanced electro-optical engines. The company specializes in graphene photonics technology, which enhances optical telecommunications, particularly in 5G and data center applications. Its solutions are characterized by high data rates, low costs, and low power consumption, making them ideal for next-generation optical transceivers. CamGraPhIC's technology is compatible with various photonic materials, including silicon and silicon nitride, and can be synthesized and integrated using scalable wafer-level processes. This capability enables clients to efficiently utilize the bandwidth necessary for emerging digital applications, such as cloud services and the Internet of Things.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

Newronika is a company dedicated to restoring brain and body functions through innovative neuro-modulation technologies. It translates extensive expertise in biosignal decoding into clinical applications aimed at enhancing treatments, health, and overall wellness. By utilizing a therapeutic device that employs a retro-activity system, Newronika records brain activity and modulates neuro-stimulation to analyze and interpret bio-signals. This technology ensures that patients receive the appropriate stimulation at critical moments, enabling them to engage in normal daily activities and improve their quality of life. Founded as a spin-off from two prominent Italian research institutions, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika prides itself on a multidisciplinary team of scientists specializing in various fields, including neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Easy Rain i.S.p.A. is an Italian company founded in 2013, based in Milan, that specializes in enhancing vehicle safety through innovative technology. It has developed a patented active safety system that addresses the hydroplaning phenomenon, which occurs when vehicles lose traction on wet roads due to a layer of water. This issue contributes to millions of accidents annually and poses significant challenges for autonomous driving technologies. Easy Rain’s system prevents excessive water from contacting the tires, thereby improving traction and overall vehicle performance in wet conditions. The company holds extensive patent coverage for its technology and offers solutions that can integrate with remote detection and vision systems to further enhance safety and efficiency for both conventional and electric vehicles.

TES Pharma is a research-based biopharmaceutical company focusses on delivering first in class preclinical candidates that unlock the potential of novel therapeutic targets and mechanisms.

D-Orbit S.r.l. is an Italian New Space company focused on providing comprehensive solutions for the satellite lifecycle, including design, development, launch, commissioning, and safe decommissioning. Established in 2011 and headquartered in Sesto Fiorentino, Italy, with additional offices in Washington, DC, and Lisbon, Portugal, D-Orbit specializes in space logistics and orbital transportation services. The company's innovative devices facilitate the safe disposal of artificial satellites at the end of their operational lives, addressing the critical issue of space debris. By streamlining satellite missions and offering services such as last-mile delivery, mission control, and space waste management, D-Orbit aims to enhance operational efficiency, reduce costs, and create a positive environmental impact while delivering value to satellite owners and operators. With a dedicated team of approximately 35 employees, D-Orbit is committed to advancing the space sector through sustainable practices and effective solutions.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Freya Biosciences is a clinical-stage women's health company headquartered in Copenhagen and Boston, specializing in the development of microbial immunotherapies. The company focuses on addressing significant unmet medical needs across various indications by utilizing a proprietary platform to engineer and manufacture live microbes. These engineered microbes are designed to be both safe and effective for human use, facilitating the creation of innovative treatments for a range of diseases.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

D-Orbit S.r.l. is an Italian New Space company focused on providing comprehensive solutions for the satellite lifecycle, including design, development, launch, commissioning, and safe decommissioning. Established in 2011 and headquartered in Sesto Fiorentino, Italy, with additional offices in Washington, DC, and Lisbon, Portugal, D-Orbit specializes in space logistics and orbital transportation services. The company's innovative devices facilitate the safe disposal of artificial satellites at the end of their operational lives, addressing the critical issue of space debris. By streamlining satellite missions and offering services such as last-mile delivery, mission control, and space waste management, D-Orbit aims to enhance operational efficiency, reduce costs, and create a positive environmental impact while delivering value to satellite owners and operators. With a dedicated team of approximately 35 employees, D-Orbit is committed to advancing the space sector through sustainable practices and effective solutions.

Easy Rain i.S.p.A. is an Italian company founded in 2013, based in Milan, that specializes in enhancing vehicle safety through innovative technology. It has developed a patented active safety system that addresses the hydroplaning phenomenon, which occurs when vehicles lose traction on wet roads due to a layer of water. This issue contributes to millions of accidents annually and poses significant challenges for autonomous driving technologies. Easy Rain’s system prevents excessive water from contacting the tires, thereby improving traction and overall vehicle performance in wet conditions. The company holds extensive patent coverage for its technology and offers solutions that can integrate with remote detection and vision systems to further enhance safety and efficiency for both conventional and electric vehicles.

Alia Therapeutics is focused on the development of next-generation gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools that allow for the correction of inborn genetic errors directly within patients' cells. By utilizing unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their root cause, enabling healthcare professionals to modify genomes effectively. Additionally, the company emphasizes the importance of safe and efficient delivery methods for these gene-editing solutions to target cells, positioning itself at the forefront of advancements in the treatment of genetic diseases.

Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company aims to provide a novel therapeutic solution for patients with mitral valve disease by offering an innovative implant technology designed for replacing incompetent mitral valves. This technology is characterized by its safety, effectiveness, and ease of use, enabling hospitals to treat patients suffering from heart valve dysfunction more efficiently.

CYSEC is a startup focused on advancing Confidential Computing solutions that ensure the security of data at rest, in motion, and in use. The company has developed a cloud-based data security software that operates as a physical enterprise-grade server appliance, enabling businesses to safeguard their assets and maintain the integrity and confidentiality of data stored in the cloud. CYSEC's flagship product, the ARCA solution, has gained popularity in the market due to its ability to support multiple applications and enhance cybersecurity across various sectors. By providing innovative tools for confidential computing, CYSEC aims to empower organizations to develop cutting-edge technological solutions while ensuring robust data protection.

CellPly is a life-science company specializing in advanced analytical tools for deep characterization of cancer immunotherapies, cell therapies, and biotherapeutics. It accelerates R&D and automates quality control processes using proprietary microfluidic technologies, Co-Culture Array technology, highly-automated instruments, and AI-powered image analytics. By defining immune system function at the single-cell level and combining functional data with multiplex data, CellPly enables personalized cancer treatment by supporting the development of novel immunotherapies and monitoring clinical responses to treatments.

Cortilia is a grocery delivery company based in Milan, Italy, founded in 2011. It operates an online agricultural marketplace that connects consumers directly with local farmers, providing access to fresh, artisanal, and seasonal products. By aggregating farmers in virtual markets, Cortilia enhances the local economy while minimizing waste. The company ensures that products are packed and delivered to customers' doors within a few hours, prioritizing quality and freshness. This sustainable approach allows consumers to easily access farm and dairy products, fostering a more direct relationship between producers and consumers.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company aims to provide a novel therapeutic solution for patients with mitral valve disease by offering an innovative implant technology designed for replacing incompetent mitral valves. This technology is characterized by its safety, effectiveness, and ease of use, enabling hospitals to treat patients suffering from heart valve dysfunction more efficiently.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

Expert.ai is a developer of enterprise natural language processing technologies that focuses on transforming language-intensive processes into actionable insights. The company's platform combines symbolic human-like understanding with machine learning, enabling organizations to enhance decision-making and streamline operations. Expert.ai offers a range of solutions, including Cogito Discover, which utilizes artificial intelligence for analytics, extraction, and categorization of text across various formats, thus facilitating automation. Additionally, the Clinical Research Navigator assists biomedical clients in advancing research into therapies for infectious diseases. The company provides its services through on-premise, private, and public cloud offerings, catering to diverse industries such as insurance, banking, publishing, defense, and life sciences.

D-Orbit S.r.l. is an Italian New Space company focused on providing comprehensive solutions for the satellite lifecycle, including design, development, launch, commissioning, and safe decommissioning. Established in 2011 and headquartered in Sesto Fiorentino, Italy, with additional offices in Washington, DC, and Lisbon, Portugal, D-Orbit specializes in space logistics and orbital transportation services. The company's innovative devices facilitate the safe disposal of artificial satellites at the end of their operational lives, addressing the critical issue of space debris. By streamlining satellite missions and offering services such as last-mile delivery, mission control, and space waste management, D-Orbit aims to enhance operational efficiency, reduce costs, and create a positive environmental impact while delivering value to satellite owners and operators. With a dedicated team of approximately 35 employees, D-Orbit is committed to advancing the space sector through sustainable practices and effective solutions.

D-Orbit S.r.l. is an Italian New Space company focused on providing comprehensive solutions for the satellite lifecycle, including design, development, launch, commissioning, and safe decommissioning. Established in 2011 and headquartered in Sesto Fiorentino, Italy, with additional offices in Washington, DC, and Lisbon, Portugal, D-Orbit specializes in space logistics and orbital transportation services. The company's innovative devices facilitate the safe disposal of artificial satellites at the end of their operational lives, addressing the critical issue of space debris. By streamlining satellite missions and offering services such as last-mile delivery, mission control, and space waste management, D-Orbit aims to enhance operational efficiency, reduce costs, and create a positive environmental impact while delivering value to satellite owners and operators. With a dedicated team of approximately 35 employees, D-Orbit is committed to advancing the space sector through sustainable practices and effective solutions.

Intrepida Bio, Inc. is a biotechnology company focused on developing innovative cancer therapies that enhance the body’s innate immune response. Founded in 2016 and headquartered in San Diego, California, the company specializes in creating medicines that modulate the innate immune system to combat cancer and other diseases. Intrepida Bio is particularly engaged in the development of monoclonal antibodies aimed at novel targets such as BAG3 and its receptor IFITM-2, which are involved in establishing a tumor-friendly environment. Through its research efforts, Intrepida Bio aims to provide patients with effective treatment options to fight cancer.

Newronika is a company dedicated to restoring brain and body functions through innovative neuro-modulation technologies. It translates extensive expertise in biosignal decoding into clinical applications aimed at enhancing treatments, health, and overall wellness. By utilizing a therapeutic device that employs a retro-activity system, Newronika records brain activity and modulates neuro-stimulation to analyze and interpret bio-signals. This technology ensures that patients receive the appropriate stimulation at critical moments, enabling them to engage in normal daily activities and improve their quality of life. Founded as a spin-off from two prominent Italian research institutions, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika prides itself on a multidisciplinary team of scientists specializing in various fields, including neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Cortilia is a grocery delivery company based in Milan, Italy, founded in 2011. It operates an online agricultural marketplace that connects consumers directly with local farmers, providing access to fresh, artisanal, and seasonal products. By aggregating farmers in virtual markets, Cortilia enhances the local economy while minimizing waste. The company ensures that products are packed and delivered to customers' doors within a few hours, prioritizing quality and freshness. This sustainable approach allows consumers to easily access farm and dairy products, fostering a more direct relationship between producers and consumers.

BiovelocITA is a business accelerator focused on enhancing the Italian biotechnology sector by supporting early-stage companies. Co-founded by Sofinnova Partners, a prominent entity in the Italian biotech landscape, BiovelocITA leverages a network of top-tier scientists, entrepreneurs, and investors to facilitate the development of innovative ventures. The organization offers comprehensive acceleration services, including mentorship, workspace, and initial funding, aimed at helping startups formulate viable business plans and achieve success in the competitive biotech market. By fostering collaboration among key stakeholders, BiovelocITA plays a crucial role in positioning Italy as a leading player in the European biotechnology arena.

UltraSoC Technologies Ltd., established in 2005 and headquartered in Cambridge, UK, specializes in semiconductor intellectual property (IP) for system monitoring, analysis, and optimization. The company's core offering is an independent, non-intrusive system-level architecture that enables real-time, wire-speed monitoring of System-on-Chip (SoC) internal behavior. This IP accelerates and de-risks development by providing engineers with insights into complex interactions between on-chip sub-systems, buses, and software. UltraSoC's toolkit comprises configurable modules and software for IP configuration, debug, and analytics, serving applications in SoC debug, analytics and optimization, in-field monitoring, and security. Since June 2020, UltraSoC operates as a subsidiary of Siemens AG.

MainStreaming is a technology company specializing in broadcast-grade live video delivery through extensive EDGE networks. It focuses on enabling large-scale live streaming operations by providing optimized solutions that enhance the viewing experience and ensure high-quality service. The company’s offerings include real-time live streaming, on-demand streaming, and multi-device delivery, supported by an API library that facilitates integration with various platforms. MainStreaming addresses critical challenges in live streaming distribution, such as congestion and security, allowing broadcasters to reach millions of concurrent users while maintaining content integrity and viewer satisfaction. By tracking content and audience key performance indicators, MainStreaming equips media strategists with essential insights to enhance performance and return on investment.

Sweetguest s.r.l., founded in 2016 and based in Milan, Italy, specializes in providing comprehensive management services for short-term rental properties. The company has developed a mobile application that streamlines the reservation process and offers a full range of services to both property owners and their guests. Sweetguest manages all aspects of short-term rentals, including reservations, check-ins, check-outs, laundry, and cleaning. By handling these tasks, Sweetguest enables property owners to maximize their earnings while saving time and effort, ensuring a high-quality experience for everyone involved.

Talent Garden is a leading digital skills academy based in Europe, founded in Italy in 2011. It aims to empower individuals and organizations by providing the knowledge, resources, and spaces necessary for thriving within the innovation ecosystem. The company offers a variety of learning experiences, including online, offline, and hybrid courses, as well as corporate programs and events. Talent Garden operates a network of coworking campuses that fosters a vibrant community of over 45,000 professionals in the digital and tech sectors. Its mission focuses on closing the digital skills gap, having successfully trained more than 25,000 individuals in areas such as digital design, marketing, product management, and cybersecurity. By collaborating with major partners, Talent Garden delivers tailored corporate education programs to promote digital transformation. Its campuses, open 24 hours a day, are designed to facilitate collaboration and provide professionals with a supportive environment to thrive and innovate.

The Data Appeal Company, established in 2014, specializes in AI-driven data analysis and visualization. Headquartered in Florence, Italy, with offices across Europe, the company collects and interprets geographical data, online feedback, customer behaviors, and trends. Its core products, Travel Appeal and Data Appeal Studio, empower businesses to understand and enhance customer experiences through real-time insights, predictive analysis, and semantic understanding. The company's mission is to democratize data usage, making it accessible and understandable for informed decision-making.

Bendit is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology. This technology provides enhanced steering capabilities in both micro diameter and conventional catheter wires and tubes. The company focuses on creating microcatheter devices that enable precise navigation within the body, allowing healthcare professionals to access targeted sites with minimal tools and reduced risks. Bendit's products are designed to improve the success rates of medical procedures by offering peripheral and visceral microcatheters that can be shaped and directed as needed. The company is a joint venture formed by three experienced groups in production, quality and regulation, and medical development, bringing together expertise to advance catheter technology.

Easy Rain i.S.p.A. is an Italian company founded in 2013, based in Milan, that specializes in enhancing vehicle safety through innovative technology. It has developed a patented active safety system that addresses the hydroplaning phenomenon, which occurs when vehicles lose traction on wet roads due to a layer of water. This issue contributes to millions of accidents annually and poses significant challenges for autonomous driving technologies. Easy Rain’s system prevents excessive water from contacting the tires, thereby improving traction and overall vehicle performance in wet conditions. The company holds extensive patent coverage for its technology and offers solutions that can integrate with remote detection and vision systems to further enhance safety and efficiency for both conventional and electric vehicles.

Bendit is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology. This technology provides enhanced steering capabilities in both micro diameter and conventional catheter wires and tubes. The company focuses on creating microcatheter devices that enable precise navigation within the body, allowing healthcare professionals to access targeted sites with minimal tools and reduced risks. Bendit's products are designed to improve the success rates of medical procedures by offering peripheral and visceral microcatheters that can be shaped and directed as needed. The company is a joint venture formed by three experienced groups in production, quality and regulation, and medical development, bringing together expertise to advance catheter technology.

UltraSoC Technologies Ltd., established in 2005 and headquartered in Cambridge, UK, specializes in semiconductor intellectual property (IP) for system monitoring, analysis, and optimization. The company's core offering is an independent, non-intrusive system-level architecture that enables real-time, wire-speed monitoring of System-on-Chip (SoC) internal behavior. This IP accelerates and de-risks development by providing engineers with insights into complex interactions between on-chip sub-systems, buses, and software. UltraSoC's toolkit comprises configurable modules and software for IP configuration, debug, and analytics, serving applications in SoC debug, analytics and optimization, in-field monitoring, and security. Since June 2020, UltraSoC operates as a subsidiary of Siemens AG.

Directa Plus S.p.A. is a nanotechnology company based in Lomazzo, Italy, founded in 2005, that specializes in the production and supply of graphene-based products for both industrial and commercial applications. The company operates through various segments, including Textile, Environmental, and Others, and offers its products under the G+ brand name. Directa Plus's innovative solutions are utilized in a wide range of applications, such as elastomers, smart textiles, polymer nanocomposites, wastewater treatment, and 3D printing. The company has developed advanced manufacturing processes to create high-quality engineered graphene products, with a significant portion of its revenue generated from the environmental segment, which includes applications in oil-spill recovery and water treatment.

CellPly is a life-science company specializing in advanced analytical tools for deep characterization of cancer immunotherapies, cell therapies, and biotherapeutics. It accelerates R&D and automates quality control processes using proprietary microfluidic technologies, Co-Culture Array technology, highly-automated instruments, and AI-powered image analytics. By defining immune system function at the single-cell level and combining functional data with multiplex data, CellPly enables personalized cancer treatment by supporting the development of novel immunotherapies and monitoring clinical responses to treatments.